First Trust Advisors LP Sells 20,975 Shares of Glaukos Co. (NYSE:GKOS)

First Trust Advisors LP reduced its stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 25.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 59,874 shares of the medical instruments supplier's stock after selling 20,975 shares during the period. First Trust Advisors LP owned 0.11% of Glaukos worth $8,978,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GKOS. Barclays PLC raised its position in shares of Glaukos by 394.4% during the third quarter. Barclays PLC now owns 89,699 shares of the medical instruments supplier's stock worth $11,686,000 after acquiring an additional 71,556 shares during the last quarter. Tidal Investments LLC raised its holdings in Glaukos by 83.1% during the 3rd quarter. Tidal Investments LLC now owns 14,908 shares of the medical instruments supplier's stock worth $1,942,000 after purchasing an additional 6,767 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Glaukos by 80.1% in the 3rd quarter. Franklin Resources Inc. now owns 15,621 shares of the medical instruments supplier's stock worth $2,031,000 after purchasing an additional 6,948 shares during the period. Exome Asset Management LLC bought a new stake in shares of Glaukos in the 3rd quarter valued at $3,369,000. Finally, GAMMA Investing LLC increased its position in shares of Glaukos by 28.3% during the fourth quarter. GAMMA Investing LLC now owns 2,213 shares of the medical instruments supplier's stock worth $332,000 after buying an additional 488 shares during the period. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Stock Up 4.9 %

NYSE GKOS traded up $4.06 on Friday, reaching $87.60. The company had a trading volume of 2,188,300 shares, compared to its average volume of 673,751. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The company's fifty day moving average is $97.60 and its 200 day moving average is $128.81. Glaukos Co. has a 52-week low of $77.10 and a 52-week high of $163.71. The stock has a market capitalization of $5.00 billion, a P/E ratio of -30.52 and a beta of 0.88.

Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. During the same quarter in the prior year, the company posted ($0.70) earnings per share. The firm's revenue for the quarter was up 24.6% on a year-over-year basis. Sell-side analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

GKOS has been the topic of a number of research analyst reports. Needham & Company LLC cut their price target on shares of Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday. Stephens cut their target price on Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday. Piper Sandler lowered their target price on Glaukos from $180.00 to $165.00 and set an "overweight" rating for the company in a report on Tuesday, April 15th. Mizuho cut their price target on Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a report on Wednesday, April 16th. Finally, Wells Fargo & Company lowered shares of Glaukos from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $160.00 to $86.00 in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, Glaukos currently has a consensus rating of "Moderate Buy" and a consensus target price of $137.62.

Insider Transactions at Glaukos

In related news, CFO Alex R. Thurman sold 1,520 shares of the firm's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the sale, the chief financial officer now owns 53,431 shares in the company, valued at approximately $5,708,568.04. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Tomas Navratil sold 3,416 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares of the company's stock, valued at $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 6.40% of the company's stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.